Anti-Cd70-Car-T Cells

Metastatic Tumor

Zhejiang UniversityCell therapyPhase 1Active

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

15 Active assets in the Metastatic Tumor cohort.

Asset / Sponsor	Phase	Rating
Ipilimumab 7 Hills Pharma, LLC	Phase 3	BB
Fludarabine Beijing Biotech	Phase 2	BB
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. NKGen Biotech, Inc.	Phase 1/2	CC
tst003 Suzhou Transcenta Therapeutics Co., Ltd.	Phase 1/2	CC
ly2334737 Eli Lilly and Company	Phase 1	CC